Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Leukemia, B-cell: full-pipeline trial registry
3 of 4 indexed Leukemia, B-cell trials are currently recruiting.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Leukemia, B-cell: 4 US clinical trials tracked, 3 recruiting.
Leukemia, B-cell is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Pharmacyclics Switzerland, running 1 of these trials.
Enrollment posture brief
Registry condition leukemia-b-cell
OPEN 3 | RECR 75% | LATE 2 | EARLY 2 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Leukemia, B-cell lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Leukemia, B-cell on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Leukemia, B-cell is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Loxo Oncology
NCT05254743
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
MacroGenics
NCT05362773
Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)
Baylor College of Medicine
NCT05010564
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Pharmacyclics Switzerland
NCT03229200
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Leukemia, B-cell records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Leukemia, B-cell trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Leukemia, B-cell page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Leukemia, B-cell trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pharmacyclics Switzerland sponsors the most Leukemia, B-cell trials on record, review their full trial history before evaluating a specific study. See Pharmacyclics Switzerland's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Leukemia, B-cell condition card totals 4 registered trials; most-linked intervention Ibrutinib; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.